SEC Form 4 · accession 0001209191-15-081528
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Chodakewitz
Officer — EVP GMDA, CMO
Period of report
Nov 18, 2015
Accepted (ET)
Nov 20, 2015 · 4:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 18, 2015 | M | 10,315 | $73.51 | A | 110,877 | D | |
| Common Stock | Nov 18, 2015 | S | 10,315 | $130.00 | D | 100,562 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $73.51 | Nov 18, 2015 | M | 10,315 | D | — | Jan 1, 2024 | Common Stock | 10,315 | 30,938 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Chodakewitz's company approved trading plan under Rule 10b5-1.
- F2The option vests in 16 quarterly installments from 01/02/2014.